Uitdehaag et al. (2016) Cell Panel Profiling Reveals Conserved Therapeutic Clusters and Differentiates the Mechanism of Action of Different PI3K/mTOR, Aurora Kinase and EZH2 Inhibitors. Molecular Cancer Therapeutics, 15 (12):3097-3109.
Uitdehaag et al. (2019) Combined cellular and biochemical profiling to identify predictive drug response biomarkers for kinase inhibitors approved for clinical use between 2013 and 2017. Molecular Cancer Therapeutics, 18 (2):470-481.
Hafner et al. (2016) Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs. Nature Methods, 13:521-527.
Iorio et al. (2016) A landscape of pharmacogenomic interactions in cancer. Cell, 166 (3):740-754.
Lawrence et al. (2014) Discovery and saturation analysis of cancer genes across 21 tumour types. Nature, 505:495-501.
Bairoch (2018) The Cellosaurus, a cell line knowledge resource. Journal of Biomolecular Techniques, 29 (2):25-38.
Memorial Sloan Kettering Cancer Center
Geoerger et al. (2017) A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors. Clinical Cancer Research, 23 (10):2433-2441.
Chen et al. (2007) Reversine increases the plasticity of lineage-committed mammalian cells. PNAS, 104 (25):10482-10487.
d’Alise et al. (2008) Reversine, a novel Aurora kinases inhibitor, inhibits colony formation of human acute myeloid leukemia cells. Molecular Cancer Therapeutics, 7 (5):1140-1149.
Santaguida et al. (2008) Dissecting the role of MPS1 in chromosome biorientation and the spindle checkpoint through the small molecule inhibitor reversine. Journal of Cell Biology, 190 (1):73-87.
Libouban et al. (2017) Stable aneuploid tumors cells are more sensitive to TTK inhibition than chromosomally unstable cell lines. Oncotarget, 8 (24):38309-38325.
Garnett et al. (2012) Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature, 483:570–575.